|
Remember to add us to your contacts list to ensure you receive our emails
|
|
|
|
|
|
|
Hello and welcome to another edition of the EMJ Oncologynewsletter, your trusted source for the latest news and developments in the closely affiliated fields of oncology and haematology. Inside you will find an abundance of updates from the cutting edge of both disciplines, including a story which details the discovery of a heritable gene mutation that can predict an individual’s susceptibility to leukaemia, as well as a report on the prevalence of malignant melanoma in the elderly. We are also drawing closer to this year’s EHA and ECC congresses, both to take place in Vienna, Austria, and EMJ is set to report on each of these in the coming months. In the meantime, however, we have included a summary of some of this year’s other major events, such as the International Symposium on Critical Bleeding in Denmark. We hope that you enjoy this newsletter, and wish you all the best for the coming months!
Articles
K Sap, P Van Trappen
In this review we highlight novel aspects of diagnostic imaging in gynaecological cancers, the paradigm shift in the surgical management of certain female pelvic cancers, as well as potential new molecular targeted therapies. In the last decade, ultra-radical surgery has been shown to increase survival in advanced ovarian cancer (OVC) when extended surgical procedures are included during primary cytoreductive surgery or at interval debulking procedures after neoadjuvant chemotherapy. In cervical cancer (CVC) and endometrial cancer (EMC) endoscopic (laparoscopic or robotic) operations have been shown to significantly reduce the morbidity without altering the cancer-related survival. Although the sentinel lymph node concept is already established in early-stage vulvar cancer, its diagnostic accuracy in EMC and CVC is still under debate. Novel molecular targeted therapies including blocking agents against new blood vessel formation (anti-angiogenesis) and polyadenosine diphosphate ribose polymerase inhibitors have been shown to prolong the progression-free survival in advanced OVC. Other molecular therapies, single or combined, are under investigation in OVC and EMC.
M Dal Bo et al.
Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease characterised by the accumulation/expansion of a clonal population of neoplastic cells with the morphological appearance of small mature B lymphocytes in blood, bone marrow, and lymphoid organs. Stimulation through the B cell receptor (BCR) plays a prominent role in the selection and expansion of the malignant clone in CLL. On the other hand, other external signals delivered by several cell types including T lymphocytes, macrophages, stromal cells, endothelial cells, and follicular dendritic cells, operating through either direct BCR-independent cell-cell contact or indirect production of paracrine soluble factors, synergistically cooperate in regulating proliferation and survival of CLL cells. In this context, CD49d is known to play a pivotal role in mediating both cell-cell and cell-matrix interactions in CLL-involved tissues, eventually delivering pro-survival signals and protecting CLL cells from drug-induced damages. In the present review, we focused on functional and physical interactions of CD49d with other microenvironmental receptors, including CD38 and BCR, and other specific CD49d-dependent interactions in lymph node and bone marrow microenvironments responsible for growth and survival-supporting signals, eventually influencing CLL prognosis and therapeutic options.
|
|
What’s Happening in EMJ: Oncology/Hematology
Our team is hard at work putting together the next editions of the EMJ Oncology and EMJ HematologyeJournals. As always, we will be working with some of the keenest minds in medicine to produce innovative, state-of-the-art content. If you would like to keep up to date with all of our projects then please do not hesitate to visit the EMJ website. You can also follow us on a number of major social media platforms, including Facebook, Twitter, and LinkedIn.
|
|
|
29th-30th June 2015
Paris, France
|
|
|
|
|
|
|
_________________________________________________________
|
|
|
European Medical Journal
Head Office – The MedBIC, Anglia Ruskin University, Alan Cherry Drive, Chelmsford, Essex, CM1 1SQ
Sales Office - Coppergate House, 16 Brune Street, London, E1 7NJ
Switchboard: +44 (0) 1245 334450
Registration No: 08198092. The information contained in this message is confidential and maybe legally privileged. It is intended for the addresses(s) only. Any unauthorised use, dissemination of the information, or unauthorised copying/forwarding of this message is prohibited. If you are not the intended addressee, please notify the sender immediately by return email and delete this message. Any views expressed in this message are those of the individual sender, except where the message states otherwise and the sender is authorised to state them.
|
|
|
_________________________________________________________
|
|
|
|
|
To ensure that you continue receiving our emails, please add us to your address book or safe list. If you are receiving this email continuously and if you think this is SPAM, please report to circulation@emjreviews.com and we will try our best to resolve your concerns. If you would like to Subscribe to receive further updates from the European Medical Journal, please follow the link at the bottom through to our automated system, alternatively if you would like to Unsubscribe please also use the link provided.
|
|
|
_newsletter.jpg)
_newsletter.jpg)
.jpg)
.png)